Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease
- PMID: 26048156
- DOI: 10.1016/j.nbd.2015.05.011
Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease
Abstract
Huntington's disease (HD) is caused by an expansion of glutamine repeats in the huntingtin protein (mHtt) that invokes early and prominent damage of the striatum, a region that controls motor behaviors. Despite its ubiquitous expression, why certain brain regions, such as the cerebellum, are relatively spared from neuronal loss by mHtt remains unclear. Previously, we implicated the striatal-enriched GTPase, Rhes (Ras homolog enriched in the striatum), which binds and SUMOylates mHtt and increases its solubility and cellular cytotoxicity, as the cause for striatal toxicity in HD. Here, we report that Rhes deletion in HD mice (N171-82Q), which express the N-terminal fragment of human Htt with 82 glutamines (Rhes(-/-)/N171-82Q), display markedly reduced HD-related behavioral deficits, and absence of lateral ventricle dilatation (secondary to striatal atrophy), compared to control HD mice (N171-82Q). To further validate the role of GTPase Rhes in HD, we tested whether ectopic Rhes expression would elicit a pathology in a brain region normally less affected in HD. Remarkably, ectopic expression of Rhes in the cerebellum of N171-82Q mice, during the asymptomatic period led to an exacerbation of motor deficits, including loss of balance and motor incoordination with ataxia-like features, not apparent in control-injected N171-82Q mice or Rhes injected wild-type mice. Pathological and biochemical analysis of Rhes-injected N171-82Q mice revealed a cerebellar lesion with marked loss of Purkinje neuron layer parvalbumin-immunoreactivity, induction of caspase 3 activation, and enhanced soluble forms of mHtt. Similarly reintroducing Rhes into the striatum of Rhes deleted Rhes(-/-)Hdh(150Q/150Q) knock-in mice, elicited a progressive HD-associated rotarod deficit. Overall, these studies establish that Rhes plays a pivotal role in vivo for the selective toxicity of mHtt in HD.
Keywords: Ataxia; Cerebellar pathology; Ectopic expression; Huntington's disease; Knock-in HD mice; Neurodegeneration; Neuronal death; Rhes; Soluble Huntingtin; Stereotaxy; Transgenic HD mice.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.Int J Mol Med. 2019 Dec;44(6):2223-2233. doi: 10.3892/ijmm.2019.4373. Epub 2019 Oct 15. Int J Mol Med. 2019. PMID: 31638189 Free PMC article.
-
Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum).Neuropharmacology. 2011 Jun;60(7-8):1187-92. doi: 10.1016/j.neuropharm.2010.10.025. Epub 2010 Oct 31. Neuropharmacology. 2011. PMID: 21044641 Review.
-
The role of Rhes, Ras homolog enriched in striatum, in neurodegenerative processes.Exp Cell Res. 2013 Sep 10;319(15):2310-5. doi: 10.1016/j.yexcr.2013.03.033. Epub 2013 Apr 10. Exp Cell Res. 2013. PMID: 23583659 Review.
-
Striatal Induction and Spread of the Huntington's Disease Protein: A Novel Rhes Route.J Huntingtons Dis. 2022;11(3):281-290. doi: 10.3233/JHD-220548. J Huntingtons Dis. 2022. PMID: 35871361 Free PMC article. Review.
-
Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.Hum Mol Genet. 2011 Jul 15;20(14):2770-82. doi: 10.1093/hmg/ddr176. Epub 2011 Apr 22. Hum Mol Genet. 2011. PMID: 21515588 Free PMC article.
Cited by
-
Deletion of SUMO1 attenuates behavioral and anatomical deficits by regulating autophagic activities in Huntington disease.Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2107187119. doi: 10.1073/pnas.2107187119. Proc Natl Acad Sci U S A. 2022. PMID: 35086928 Free PMC article.
-
Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion.J Cell Biol. 2019 Jun 3;218(6):1972-1993. doi: 10.1083/jcb.201807068. Epub 2019 May 10. J Cell Biol. 2019. PMID: 31076452 Free PMC article.
-
Global Rhes knockout in the Q175 Huntington's disease mouse model.PLoS One. 2021 Oct 14;16(10):e0258486. doi: 10.1371/journal.pone.0258486. eCollection 2021. PLoS One. 2021. PMID: 34648564 Free PMC article.
-
Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics.Mol Neurobiol. 2021 Dec;58(12):6350-6377. doi: 10.1007/s12035-021-02556-x. Epub 2021 Sep 14. Mol Neurobiol. 2021. PMID: 34519969 Review.
-
Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.Drug Des Devel Ther. 2015 Oct 28;9:5827-33. doi: 10.2147/DDDT.S65738. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26604684 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials